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Abstract 
Given the importance of correctly staging renal cell carcinomas, specific guidelines should be in 
place for tumor size measurement. While a standard means of renal tumor measurement has not 
been established, intuitively, tumor size should be based on fresh measurements. We sought to 
assess the accuracy of postfixation and microscopic measurements of renal tumor size, as com-
pared to fresh measurements and radiographic size. Thirty-four nephrectomy cases performed by 
a single surgeon were prospectively measured at different time points. The study cases included 23 
clear cell renal cell carcinomas, 6 papillary renal cell carcinomas, and 5 other renal tumors. Ra-
diologic tumors were 12.1% larger in diameter than fresh tumors (P<0.01). Furthermore, fresh 
specimens were 4.6% larger than formalin-fixed specimens (P<0.01), and postfixation measure-
ments were 7.1% greater than microscopic measurements (P<0.01). The overall mean percentage 
of shrinkage between fresh and histological specimens was 11.4% (P<0.01). Histological processing 
would cause a tumor stage shift from pT1b to pT1a for two tumors in this study. The shrinkage 
effects of formalin fixation and histological processing may result in understaging of renal cell 
carcinomas. The shrinkage factor should be considered when reporting tumor size. 
Key words: Kidney; renal cell carcinoma; tissue processing shrinkage; tumor size measurement; 
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Introduction 
Kidney cancer is currently the sixth and eighth 
most common cause of new cancer diagnoses in 
American men and women, respectively, and the in-
cidence has increased by approximately 3% 
annually.[1-5] In particular, the rate of renal cell car-
cinoma has steadily increased over the past several 
decades, and renal cell carcinomas are currently one 
of the most lethal tumors of the genitourinary sys-
tem.[6] The tumor, nodes, and metastasis (TNM) 
staging system for renal cell carcinoma has evolved 
over the years in an effort to be more prognostically 
relevant as new research has emerged.[7-10] In 2002, 
the pT1 group was subdivided into a pT1a category 
for tumors measuring 4 cm or less and pT1b for larger 
tumors measuring up to 7 cm. Recently, in 2010, the 
pT2 division was similarly refined with tumors 
measuring greater than 7 and up to 10 cm placed in a 
pT2a category, and those larger than 10 cm being 
staged as pT2b.[11] In the upcoming 4th edition of the 
World Health Organization (WHO) Classification of 
Tumors of the Urinary System and Male Genital Or-








posed to distinguish renal papillary adenoma from 
papillary renal cell carcinoma, though it is unclear if 
the tumor size should be based on fresh, postfixation, 
or microscopic measurement. 
Given the fact that tumor size plays a key role in 
staging renal cell carcinomas, specific guidelines 
should be in place for tumor measurement.[6, 9-14] 
The TNM classification method has evolved from the 
nonspecific size distinctions of “small” and “large” to 
further subclassifications of specific tumor size cutoffs 
that may affect prognosis and treatment, but clear 
definitions of how to obtain these size measurements 
are lacking.[6, 9-14] We sought to quantify the effects 
of formalin fixation, tissue processing and mounting 
of histologic sections on tumor size in a prospective 
study.  
Materials and Methods 
From the period of October 3, 2013 to November 
20, 2014, all nephrectomy cases performed by a single 
urologist (CPS) at our institution were prospectively 
measured at different time points. At the end of sur-
gery, the fresh specimen was sectioned and meas-
urements of the tumor’s three dimensions were taken 
by the urologist (CPS) with the assistance of pathol-
ogy assistants and surgical pathologists. The most 
representative cross-section that included the tumor’s 
largest dimension was selected and marked with ink. 
In order to accurately measure the tumor histologi-
cally by whole mount, only postresection renal neo-
plasms grossly measuring 5.5 cm or less were in-
cluded in the study. The kidney specimen was then 
placed in 10% formalin and allowed to fix for a time 
period ranging from 6 to 24 hours. After fixation, an-
other set of three dimensional measurements were 
taken. Two-dimensional measurements of the selected 
cross-section were also recorded. The representative 
cross-section, along with the standard tissue sections 
taken for diagnosis and staging, underwent dehydra-
tion, clearing, paraffin wax embedding, section cut-
ting, mounting, and staining with hematoxylin and 
eosin. A whole mount glass slide or standard glass 
slide section was made of the most representative 
cross-section, and two-dimensional tumor size was 
measured (TT) (Fig 1). All measurements were made 
using a plastic metric ruler at 1 mm precision. Tumors 
that were too large to fit a whole mount slide (fresh 
tumor size>5.5 cm), whose cross-sections did not in-
clude the largest dimension, or whose most repre-
sentative cross-section was mistakenly incised and 
transferred to multiple slides were excluded. In addi-
tion, preoperative computerized tomography (CT) 
and magnetic resonance imaging (MRI) images were 
retrospectively reviewed (CDB) to obtain radiologic 
renal tumor measurements in three dimensions. Both 
axial and coronal/sagittal reformats were utilized in 
an effort to acquire the most accurate greatest dimen-
sion. All investigators were blinded to previously 
recorded measurements. Clinicopathologic infor-
mation, including each patient’s age, gender, type of 
surgery, tumor histologic subtype and pathologic 
staging classification, was recorded. Prior to the initi-
ation of this prospective study, the protocol was re-
viewed and approved by the Indiana University In-
stitutional Review Board. All local, state, and federal 
guidelines for the protection of human subjects were 
strictly maintained throughout the course of the 
study. 
 
Figure 1. Pictorial representation of the sequential outcomes of renal tumor 
fixation and processing. A: The transversally sectioned renal tumor specimen 
immediately after resection; B: The corresponding transversally sectioned renal 
tumor specimen after fixation in 10% formalin; and C: Microscopic section of 
the renal tumor specimen on a whole mount hematoxylin and eosin glass slide  




Descriptive statistics were utilized to describe 
differences in diameter between the four stages of 
measurement. Student t test was used to compare the 
percentage of tumor shrinkage between each of the 
measurement groups. All statistical analyses were 
performed using STATA version 12.1 (Stata Corp. LP, 
College Station, TX) and P values <0.05 were consid-
ered statistically significant. All P values were 
two-sided. 
Utilizing the resulting mean shrinkage values in 
tumor diameter between the three stages of meas-
urement, corresponding conversion factors were cal-
culated based on the formula: 1/(1-(shrinkage deci-
mal)).[15]  
Results 
A total of 34 renal tumors were included in the 
study, which consisted of 23 clear cell renal cell car-
cinomas, 6 papillary renal cell carcinomas, 1 chro-
mophobe renal cell carcinoma, 1 t(6;11) renal cell car-
cinoma, and 3 oncocytomas. All cases were partial 
nephrectomies from a total of 16 women and 18 men. 
The ages of the patients ranged from 37 to 84 years old 
with a mean age of 64 years. Two clear cell renal cell 
carcinomas were staged as pT3a. Two tumors, a clear 
cell and a chromophobe renal cell carcinoma, were 
staged as pT1b. The remaining tumors, except for the 
3 oncocytomas, were staged as pT1a.  
The tumor diameters for postresection (fresh) 
specimens ranged from 1-5.1 cm (average, 2.7 cm) 
with 7 tumors measuring less than 2 cm, 23 between 
2-4 cm, and 4 larger than 4 cm. Fixed tumor diameters 
ranged from 1-4.8 cm (average, 2.5 cm) with 8 tumors 
measuring less than 2 cm, 22 between 2-4 cm, and 4 
larger than 4 cm. Microscopic tumor diameters ranged 
from 1-4.6 cm (average, 2.3 cm), and 13 tumors meas-
ured less than 2 cm, 19 between 2-4 cm, and 2 larger 
than 4 cm.  
The average decrease in tumor diameter for fixed 
specimens, as compared to fresh, was 0.1 cm (range, 
0–0.8 cm) with a mean shrinkage of 4.6% (P<0.01) 
(range, 0–18.2%). Furthermore, the average decrease 
in diameter for histological specimens, as compared to 
fixed tumors, was 0.2 cm (range, 0–0.7 cm) with a 
mean shrinkage of 7.1% (P<0.01) (range, 0–18.2%). 
The overall average decrease in tumor diameter be-
tween fresh and histological specimens was 0.3 cm 
(range, 0–1.1 cm) with a mean shrinkage of 11.4% 
(P<0.01) (range, 0–22.7%) (Fig 2).  
CT and MRI scans were obtained at an average 
of 2.4 months before surgery. The tumor diameters 
based on radiologic imaging ranged from 1.5–5.7 cm 
(average, 3.0 cm) with 5 tumors measuring less than 2 
cm, 24 between 2 and 4 cm, and 5 larger than 4 cm. 
Radiologic tumor diameters averaged 0.4 cm larger 
than fresh tumor diameters. This corresponds to a 
mean shrinkage of 12.1% between radiologic and 
postresection measurements.  
Table 1 illustrates the utilization of our calcu-
lated correction factors. In terms of tumor diameter 
measurements, a conversion factor of 1.08 will ac-
count for shrinkage due to histological processing 
alone, 1.05 will correct formalin fixation shrinkage, 
and 1.13 will account for shrinkage from both fixation 
and tissue processing. Table 2 is a conversion table 
that provides precalculated fixed and fresh tumor 
diameters based on microscopic measurements, uti-
lizing the aforementioned correction factors.  
 
Table 1. Formulae for correcting measurements of renal cell 
carcinomas taken outside of the postresection (fresh) state§ 
Tumor Diameter (D) 
Microscopic Measure-
ment 
Postfixation Size Fresh Size 
AD* AD x 1.08 
BDǂ 
AD x 1.13 
BD x 1.05 
§ See the Methods section for the description of correction factor calculations 
*A: Size of renal tumor as measured on glass slides 
ǂ B: Size of renal tumor as measured grossly, post-formalin fixation 
 
Table 2. Conversion table for renal cell carcinoma diameter 
measurements taken outside of the postresection (fresh) state 
Microscopic Tumor 
Measurement 
Postfixation Tumor Size Fresh Tumor Size 
1.0 cm 1.1 cm 1.1 cm 
1.2 cm 1.3 cm 1.4 cm 
1.4 cm 1.5 cm 1.6 cm 
1.6 cm 1.7 cm 1.8 cm 
1.8 cm 1.9 cm 2.0 cm 
2.0 cm 2.2 cm 2.3 cm 
2.2 cm 2.4 cm 2.5 cm 
2.4 cm 2.6 cm 2.7 cm 
2.6 cm 2.8 cm 2.9 cm 
2.8 cm 3.0 cm 3.2 cm 
3.0 cm 3.2 cm 3.4 cm 
3.2 cm 3.5 cm 3.6 cm 
3.4 cm 3.7 cm 3.8 cm 
3.6 cm 3.9 cm 4.1 cm 
3.8 cm 4.1 cm 4.3 cm 
4.0 cm 4.3 cm 4.5 cm 
4.2 cm 4.5 cm 4.7 cm 
4.4 cm 4.8 cm 5.0 cm 
4.6 cm 5.0 cm 5.2 cm 
4.8 cm 5.2 cm 5.4 cm 
5.0 cm 5.4 cm 5.7 cm 
5.2 cm 5.6 cm 5.9 cm 
5.4 cm 5.8 cm 6.1 cm 
5.6 cm 6.0 cm 6.3 cm 
5.8 cm 6.3 cm 6.6 cm 
6.0 cm 6.5 cm 6.8 cm 
6.2 cm 6.7 cm 7.0 cm 
6.4 cm 6.9 cm 7.2 cm 
6.6 cm 7.1 cm 7.5 cm 
6.8 cm 7.3 cm 7.7 cm 
7.0 cm 7.6 cm 7.9 cm 
 





Figure 2. Average linear shrinkage in tumor diameter from radiologic imaging to final processed state. Tumor size relative to postresection (fresh) diameter is 
illustrated here. Fresh tumors (orange) are considered the gold standard in terms of size and are represented as 100% of the diameter. Mean radiologic (green), 
postfixation (blue), and microscopic glass slide (gray) measurements are represented as percentage differences from the gold standard. Standard error bars and P 
values between each group pairing are provided. Y axis represents tumor size relative to postresection diameter. 
 
Discussion 
Since the inception of staging systems for renal 
cell carcinomas and their evolution over the past 50 
years, staging remains an important prognostic indi-
cator.[6, 9-14] The first classification method was in-
troduced by Flocks and Kadesky in 1958, which con-
centrated on the extent of tumor spread.[16] The TNM 
staging system was established in 1978 and intro-
duced tumor size as a prognostic factor.[10, 11] The 
TNM system for renal cell carcinoma has been revised 
multiple times to be more prognostically precise, 
changing the T2 tumor size cutoff points from “large” 
to greater than 2 cm and then to greater than 7 cm.[6, 
9-14] In addition, T1 and T2 tumors were each further 
subcategorized into “a” and “b” stages by the TNM 
system with the cutoffs placed at 4 cm and 10 cm, 
respectively.[10, 11] Tumor size has repeatedly been 
shown to be a significant prognostic indicator, even 
independent of pathologic stage.[8, 17] Larger renal 
cell carcinomas are significantly more likely to have 
renal sinus invasion, ipsilateral adrenal involvement, 
synchronous metastasis, and an overall decreased 
5-year survival rate.[18-22] According to Bonsib and 
Bhalodia, unrecognized retrograde vein invasion may 
have partially contributed to the reportedly worse 
prognosis associated with larger renal tumors, whose 
size may have been inflated with confluent nodules of 
intravenous cancer.[23] Correct renal tumor meas-
urement remains essential for accurate prognostica-
tion.  
Tumor size plays a key role in renal cell carci-
noma staging, and its importance has grown 
throughout TNM’s evolution with the additions of 
further subdivisions according to size.[6, 9-14] Despite 
this, a standardized means of tumor measurement has 
not been established. While, intuitively, staging a re-
nal cell carcinoma should be based on fresh tumor 
measurements, most pathologists report size based on 
postfixation or, for small tumors, microscopic meas-
urements. 
Our results demonstrate that formalin fixation 
can shrink renal tumors, and the steps of histological 
processing, embedding and mounting cause even 
further tumor shrinkage. Formalin acts by diffusing 
through the tissue and binding to amino groups, pre-
cipitating the formation of an extensive network of 
cross-linked proteins and nucleic acids, which can 
cause histological changes, such as cell shrinkage and 
distortion.[24] Conceivably, these cellular changes can 




have a global effect on the whole tissue specimen. 
While the effects of fixation and histological pro-
cessing on specimen size have not been previously 
systematically studied in the kidney, there are a small 
number of similar studies performed on other organ 
systems. Several of these studies also found a 
shrinkage effect of formalin for various tissue speci-
mens. Our mean 4.6% tumor diameter shrinkage after 
fixation is greater than the 2.7% found for cervical 
tissue, but smaller than that reported in most studies, 
which have ranged from approximately 8–20%.[25-31] 
This formalin-induced shrinkage effect occurred in a 
range of specimens, including those from the lung, 
gastrointestinal system, oral cavity, vulva and 
breast.[24, 26-33] This has not been consistent, how-
ever, with several studies reporting no shrinkage after 
fixation for skin, breast and gastrointestinal speci-
mens.[34-41] One paper found an increase in one di-
mension for forelimb specimens, which flattened due 
to gravity after formalin fixation, causing an increase 
in width, but a decrease in height.[42] The varying 
study results may be explained by the different types 
of tissues and tumors along with differences in for-
malin concentration and fixation time. 
A small subset of studies has evaluated the ef-
fects of histological processing. After formalin fixa-
tion, there are several steps that may affect tissue size 
as the tissue section progresses to the final staining 
phase. Tissue shrinkage may occur as the section un-
dergoes alcohol dehydration.[15] In addition, during 
the embedding stage, the tissue may be compressed if 
the paraffin is too warm and undergo extra shrinkage 
during the cooling process. During section cutting, a 
loose or off-angled microtome knife may result in 
tissue compression or chatter, and the tissue may not 
evenly spread in a cool water bath during the 
mounting stage.[39] In our study, the average per-
centage of shrinkage in tumor diameter from the fixed 
to the histological states was 7.1%, and the overall 
mean shrinkage was 11.4% between the fresh and 
microscopic measurements. In the previously pub-
lished studies, the percentage of shrinkage from the 
fixed to the microscopic measurements ranged from 
approximately 10% to 27%, and the overall percentage 
of shrinkage from fresh to microscopic measurements 
ranged from 4.5% to 41%.[15, 25, 31, 32, 39] The tissue 
types studied included cervical, gastrointestinal, 
prostatic, breast and oral cavity specimens. Pritt et al. 
found both substantial increases and decreases in 
breast tumor size with histological processing, and 
Johnson et al. reported that mucosal margins of oral 
cavity specimens did not change with slide prepara-
tion, but the deep muscular margin shrank by 
9.8%.[27, 39] Variations in tissue type and, even more 
so, in laboratory practices and processes, such as dif-
ferences in water bath temperature and the time tissue 
sections spend in warm water[15] or the practice of 
sectioning suboptimally fixed and processed tissue 
[39], may explain the varying findings. 
The subjects of the published studies are highly 
variable and include animal models, non-neoplastic 
tissue, and human tumors ranging from skin to breast 
malignancies. While studying animals and normal 
tissues may provide useful background information, 
research involving human tumors would have the 
most impact on patient care. Certain tumors, though, 
such as breast carcinomas, may have significant infil-
tration that can be difficult to gauge during gross 
tumor measurement. Such measurements may un-
derestimate the true size of the neoplasm. Other tu-
mors, such as lung and colorectal carcinomas, may be 
too large to lend feasibility to studies comparing fresh 
and fixed measurements with microscopic measure-
ments. Renal neoplasms, on the other hand, offer an 
ideal model for tumor measurement analysis due to 
their easily visualized, often circumscribed, and 
unifocal nature. In addition, the steady increase in  
renal cell carcinoma incidence due to the detection of 
small incidental kidney tumors by routine radiologi-
cal studies translates to the finding that many renal 
tumors are small enough to offer a complete, repre-
sentative cross-section on a standard glass or whole 
mount slide.[43] The kidney is also a dense, solid, 
encapsulated organ that is neither characterized by 
the elasticity of skin and the gastrointestinal tract, nor 
the almost semisolid nature of adipose tissue. Hence, 
the kidney often preserves the renal tumor’s overall 
configuration, whether solid or cystic, after removal 
and fixation. On the other hand, differences in renal 
tumor architecture, including the presence of fibrosis, 
cystic change, hemorrhage, and necrosis, may affect 
the extent of shrinkage. To the best of the authors’ 
knowledge, our study is the first to describe renal 
tumors as a model for postfixation and processing 
shrinkage analysis. 
Irrespective of the differences in subject matter 
and tissue types of the published reports, many of 
these studies were implemented because tumor size 
or margin status is essential for staging and prognosis 
in their respective organ systems, and most staging 
systems do not specify the method for measurement. 
For kidney tumors in particular, our results empha-
size the importance of establishing a standard means 
of tumor measurement. Two of our cases would re-
ceive a different pT1 classification depending on 
which measurement was used for staging. Tumor size 
has repeatedly been shown to be a significant prog-
nostic indicator.[8] Larger renal cell carcinomas in-
cluded in the T1b category are significantly more 
likely to have renal sinus invasion, ipsilateral adrenal 




involvement, synchronous metastasis, and an overall 
decreased 5-year survival rate.[18-21] Given the im-
portance of correctly staging renal cell carcinomas, 
specific guidelines should be in place for tumor 
measurement. Intuitively, renal tumors should be 
measured before placement in formalin for the most 
accurate tumor staging. However, studies reporting 
on the prognostic significance of tumor size fre-
quently do not specify how or when measurements 
were obtained.[9, 44]  
Due to the fact that taking fresh tumor meas-
urements may not always be convenient or feasible, a 
conversion factor would be a useful tool for practicing 
pathologists. For example, Silverman et al. found 20% 
shrinkage of melanoma excisions after fixation. Be-
cause minimum margins are essential for treatment, 
the authors calculated a formula to estimate in vivo 
margins from fixed-tissue measurements for mela-
noma excisions.[45] Furthermore, in the prostate, tu-
mor volume is an essential staging and prognostic 
indicator.[15] Tissue shrinkage from processing has 
long been recognized and various correction factors 
have been proposed for accurate tumor volume cal-
culations, ranging from 1.14–1.5.[46, 47] The methods 
that engendered these prostate volume correction 
factors varied and included computer planimetry, 
water displacement, transrectal ultrasound, and direct 
measurements.[46, 47] In terms of the kidney, our 
results demonstrate an average 4.6% shrinkage in 
diameter between fresh and fixed tumor measure-
ments, 7.1% between fixed and glass slide measure-
ments, and 11.4% between fresh and glass slide 
measurements, which correlate to correction factors of 
1.05, 1.08, and 1.13, respectively. The following ex-
ample illustrates the correction of shrinkage effects on 
a kidney tumor that measures 2 cm on the glass slide. 
By using the linear conversion factors, the postfixation 
diameter would equate to 2.2 cm and the postresec-
tion diameter 2.3 cm (Table 2). While fresh tumors 
measuring greater than 5.5 cm were excluded from 
the study due to decreased accuracy in terms of his-
tologic measurement, the conversion factors may be 
applicable for such tumors and the measurements 
were extrapolated and also provided in Table 2.  
Papillary adenomas of the kidney are defined as 
small, low grade, unencapsulated tumors with papil-
lary or tubular architecture that measure no larger 
than 1.5 cm. This size cutoff will be proposed in the 
upcoming 4th edition of the WHO Classification of 
Tumors of the Urinary System and Male Genital Or-
gans, but the method of measurement remains unde-
fined. If one were to apply the correction factors to a 
renal papillary tumor measuring 1.4 cm in diameter 
on the glass slide, the corresponding postfixation 
diameter would equal 1.5 cm and postresection di-
ameter 1.6 cm (Table 2). Using the microscopic 
measurement, the tumor in our example would be 
diagnosed as a papillary adenoma. But by utilizing 
the conversion factor to account for shrinkage from 
the fresh state, the tumor could be diagnosed as a pa-
pillary renal cell carcinoma. Currently, small papillary 
tumors of the kidney are likely to be diagnosed using 
gross, postfixation or microscopic measurements. 
When the definition of a benign tumor versus a ma-
lignant neoplasm is so narrow, correction factors are 
especially pertinent for accurate diagnosis. 
Kidney tumors provide an ideal model to ana-
lyze the shrinkage effects of fixation and processing. 
Our results suggest that renal cell carcinomas with 
diameters at TNM staging thresholds may be under-
staged if postfixation or microscopic measurements 
are utilized. Use of a correction factor may prevent 
such errors. For renal tumors, we recommend using a 
tumor diameter conversion factor of 1.05 for postfixa-
tion gross measurements or 1.13 for microscopic 
measurements to approximate the fresh tumor size 
more accurately. Furthermore, with an average dif-
ference of 12.1% in diameter, our results demonstrate 
that tumor measurements based on radiologic imag-
ing may overestimate the size of renal neoplasms 
when compared to the gold standard (fresh) meas-
urements. Our outcomes are in line with those of 
previous studies that found radiographic measure-
ments of renal masses to be larger than pathologic 
measurements, especially for smaller tumors.[48-58] 
While the size differences between radiologic and 
pathologic measurements may be statistically signifi-
cant in a majority of these studies, the clinical signifi-
cance in terms of treatment outcomes is uncertain.[49, 
52, 53, 57] Nevertheless, the utilization of correction 
factors for pathologic specimens would increase ac-
curacy for correlations with presurgical imaging 
measurements often used in clinical studies. Most 
importantly, conversion factors would be valuable for 
the placement of renal cell carcinomas in the appro-
priate pathologic tumor stage.  
While a standard means of renal tumor meas-
urement has not been established, intuitively, tumor 
size should be based on fresh measurements. The 
shrinkage effects of formalin fixation and histological 
processing may result in understaging of renal cell 
carcinomas. It would be helpful if future reports of the 
prognostic significance of pathologic stage for renal 
cell carcinomas included details on the method for 
tumor size measurement, especially for small renal 
tumors. 
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